154 related articles for article (PubMed ID: 38609935)
1. Selective omission of sentinel lymph node biopsy in mastectomy for ductal carcinoma in situ: identifying eligible candidates.
Bae SJ; Kook Y; Jang JS; Baek SH; Moon S; Kim JH; Lee SE; Kim MJ; Ahn SG; Jeong J
Breast Cancer Res; 2024 Apr; 26(1):65. PubMed ID: 38609935
[TBL] [Abstract][Full Text] [Related]
2. Necessity of sentinel lymph node biopsy in ductal carcinoma in situ patients: a retrospective analysis.
Shin YD; Lee HM; Choi YJ
BMC Surg; 2021 Mar; 21(1):159. PubMed ID: 33752671
[TBL] [Abstract][Full Text] [Related]
3. The Influence of Hospital and Surgeon Factors on the Prevalence of Axillary Lymph Node Evaluation in Ductal Carcinoma In Situ.
Coromilas EJ; Wright JD; Huang Y; Feldman S; Neugut AI; Chen L; Hershman DL
JAMA Oncol; 2015 Jun; 1(3):323-32. PubMed ID: 26181180
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of Omitting Sentinel Lymph Node Biopsy in an Under-screened Cohort of Breast Cancer Patients With a Premastectomy Diagnosis of Ductal Carcinoma In Situ.
Pang J; Yan Z; Tan QT; Allen JC; Wang M; Lim GH
Clin Breast Cancer; 2024 Jun; 24(4):363-367. PubMed ID: 38458843
[TBL] [Abstract][Full Text] [Related]
5. Is Sentinel Lymph Node Biopsy Necessary for Ductal Carcinoma In Situ Patients Undergoing Mastectomy?
Miller-Ocuin JL; Howard-McNatt M; Levine EA; Chiba A
Am Surg; 2020 Aug; 86(8):955-957. PubMed ID: 32862671
[TBL] [Abstract][Full Text] [Related]
6. Does sentinel lymph node biopsy for screening high-grade ductal carcinoma in situ of the breast cause more harm than good?
Ramzi S; Najeeb E; Coulthard J; Jenkins S
Breast Cancer Res Treat; 2020 Jul; 182(1):47-54. PubMed ID: 32430678
[TBL] [Abstract][Full Text] [Related]
7. Predictive factors of axillary positive sentinel lymph node biopsy in extended ductal carcinoma in situ treated by simple mastectomy at once.
Hotton J; Salleron J; Rauch P; Buhler J; Pierret M; Baumard F; Leufflen L; Marchal F
J Gynecol Obstet Hum Reprod; 2020 Mar; 49(3):101641. PubMed ID: 31562936
[TBL] [Abstract][Full Text] [Related]
8. Trends and clinicopathological predictors of axillary evaluation in ductal carcinoma in situ patients treated with breast-conserving therapy.
Huang NS; Si J; Yang BL; Quan CL; Chen JJ; Wu J
Cancer Med; 2018 Jan; 7(1):56-63. PubMed ID: 29271113
[TBL] [Abstract][Full Text] [Related]
9. Predictors of treatment with mastectomy, use of sentinel lymph node biopsy and upstaging to invasive cancer in patients diagnosed with breast ductal carcinoma in situ (DCIS) on core biopsy.
Chin-Lenn L; Mack LA; Temple W; Cherniak W; Quinn RR; Ravani P; Lewin AM; Quan ML
Ann Surg Oncol; 2014 Jan; 21(1):66-73. PubMed ID: 24046105
[TBL] [Abstract][Full Text] [Related]
10. Sentinel lymph node positivity in patients undergoing mastectomies for ductal carcinoma in situ (DCIS).
Price A; Schnabel F; Chun J; Kaplowitz E; Goodgal J; Guth A; Axelrod D; Shapiro R; Mema E; Moy L; Darvishian F; Roses D
Breast J; 2020 May; 26(5):931-936. PubMed ID: 31957944
[TBL] [Abstract][Full Text] [Related]
11. Sentinel lymph node biopsy in contralateral prophylactic mastectomy: are we overtreating? Experience at a tertiary care hospital.
Kuwajerwala NK; Dekhne NS; Pentiak PA; Fend D; Callahan RE; Amine M; Lucia V; Swartz J
Clin Breast Cancer; 2013 Aug; 13(4):287-91. PubMed ID: 23706482
[TBL] [Abstract][Full Text] [Related]
12. A N0 Predicting Model for Sentinel Lymph Node Biopsy Omission in Early Breast Cancer Upstaged From Ductal Carcinoma in Situ.
Yoo TK; Kim SJ; Lee J; Lee SB; Lee SJ; Park HY; Park HK; Chae BJ; Eom YH; Kim HS; Song BJ
Clin Breast Cancer; 2020 Jun; 20(3):e281-e289. PubMed ID: 32147404
[TBL] [Abstract][Full Text] [Related]
13. Axillary evaluation is not warranted in patients preoperatively diagnosed with ductal carcinoma in situ by core needle biopsy.
Si J; Guo R; Huang N; Xiu B; Zhang Q; Chi W; Wu J
Cancer Med; 2019 Dec; 8(18):7586-7593. PubMed ID: 31660702
[TBL] [Abstract][Full Text] [Related]
14. Is Sentinel Lymph Node Biopsy Indicated at Completion Mastectomy for Ductal Carcinoma In Situ?
Pilewskie M; Karsten M; Radosa J; Eaton A; King TA
Ann Surg Oncol; 2016 Jul; 23(7):2229-34. PubMed ID: 26960927
[TBL] [Abstract][Full Text] [Related]
15. Ductal carcinoma in situ: value of sentinel lymph node biopsy.
Sakr R; Barranger E; Antoine M; Prugnolle H; Daraï E; Uzan S
J Surg Oncol; 2006 Oct; 94(5):426-30. PubMed ID: 16967457
[TBL] [Abstract][Full Text] [Related]
16. Superparamagnetic iron oxide (SPIO) for axillary mapping in patients with ductal carcinoma in situ undergoing mastectomy: single-institution experience.
Addae JK; Sweeting RS; Meszoely IM; McCaffrey RL; Kauffmann RM; Kelley MC; Grau AM; Hewitt K
Breast Cancer Res Treat; 2024 Feb; 204(1):117-121. PubMed ID: 38087058
[TBL] [Abstract][Full Text] [Related]
17. Upstaging to invasive ductal carcinoma after mastectomy for ductal carcinoma in situ: predictive factors and role of sentinel lymph node biopsy.
Watanabe Y; Anan K; Saimura M; Koga K; Fujino M; Mine M; Tamiya S; Nishihara K; Nakano T; Mitsuyama S
Breast Cancer; 2018 Nov; 25(6):663-670. PubMed ID: 29786772
[TBL] [Abstract][Full Text] [Related]
18. Sentinel lymph node biopsy is not necessary in patients diagnosed with ductal carcinoma in situ of the breast by stereotactic vacuum-assisted biopsy.
Kotani H; Yoshimura A; Adachi Y; Ishiguro J; Hisada T; Ichikawa M; Gondou N; Hattori M; Kondou N; Sawaki M; Fujita T; Iwata H
Breast Cancer; 2016 Mar; 23(2):190-4. PubMed ID: 24989112
[TBL] [Abstract][Full Text] [Related]
19. Role of sentinel lymph node biopsy in ductal carcinoma-in-situ treated by mastectomy.
Tan JC; McCready DR; Easson AM; Leong WL
Ann Surg Oncol; 2007 Feb; 14(2):638-45. PubMed ID: 17103256
[TBL] [Abstract][Full Text] [Related]
20. The use of sentinel lymph node biopsy in the treatment of breast ductal carcinoma in situ: A Danish population-based study.
Holm-Rasmussen EV; Jensen MB; Balslev E; Kroman N; Tvedskov TF
Eur J Cancer; 2017 Dec; 87():1-9. PubMed ID: 29096155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
